These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2062464)

  • 1. Inhibition of the rate-limiting enzyme in cholesterol biosynthesis leads to up-regulation of the LDL receptor.
    Nutr Rev; 1991 May; 49(5):153-6. PubMed ID: 2062464
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
    Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
    Ness GC; Zhao Z; Lopez D
    Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver.
    Powell EE; Kroon PA
    J Clin Invest; 1994 May; 93(5):2168-74. PubMed ID: 8182149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
    Vaziri ND; Liang K
    Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
    Liang K; Kim CH; Vaziri ND
    Am J Physiol Renal Physiol; 2005 Mar; 288(3):F539-44. PubMed ID: 15507547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developmental regulation of the expression of genes encoding proteins involved in cholesterol homeostasis.
    Ness GC
    Am J Med Genet; 1994 May; 50(4):355-7. PubMed ID: 8209915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of pravastatin on hepatic cholesterol metabolism].
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    Fortschr Med; 1991 Mar; 109(8):189-94. PubMed ID: 1905265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions.
    Vaziri ND; Liang K; Azad H
    J Pharmacol Exp Ther; 2000 Aug; 294(2):778-83. PubMed ID: 10900260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of using gene expression in mononuclear cells as a marker for hepatic cholesterol metabolism.
    Aggarwal D; Freake HC; Soliman GA; Dutta A; Fernandez ML
    Lipids Health Dis; 2006 Aug; 5():22. PubMed ID: 16911794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
    Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
    Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased gene expression of liver SREBP-2 in experimental chronic renal failure.
    Chmielewski M; Sucajtys-Szulc E; Kossowska E; Swierczynski J; Rutkowski B; Boguslawski W
    Atherosclerosis; 2007 Apr; 191(2):326-32. PubMed ID: 16814791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of hepatic HMG CoA reductase activity and LDL receptor relative mass in suckling and adult guinea pigs.
    Hamilton JJ; Auestad N; Innis SM
    Biol Neonate; 1994; 65(5):317-25. PubMed ID: 8054400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological feedback regulation of cholesterol biosynthesis: Role of translational control of hepatic HMG-CoA reductase and possible involvement of oxylanosterols.
    Ness GC
    Biochim Biophys Acta; 2015 May; 1851(5):667-73. PubMed ID: 25701719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 15-oxa-32-vinyl-lanost-8-ene-3 beta,32 diol on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase and low density lipoprotein receptor in rat liver.
    Ness GC; Lopez D; Chambers CM; Zhao Z; Beach DL; Ko SS; Trzaskos JM
    Arch Biochem Biophys; 1998 Sep; 357(2):259-64. PubMed ID: 9735166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of action of hypolipemic drugs].
    Fruchart JC
    J Pharm Belg; 1992; 47(4):345-50. PubMed ID: 1403601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of plasma cholesterol by compactin and mevinolin.
    Nutr Rev; 1985 Sep; 43(9):266-8. PubMed ID: 3903562
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages.
    Fuhrman B; Elis A; Aviram M
    Biochem Biophys Res Commun; 1997 Apr; 233(3):658-62. PubMed ID: 9168909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.